# 10/559610 IAP9 Rec'd PCT/PTO 02 DEC 2005

Atty. Dkt. No. 052209-0143

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Marco FILICORI

Title:

UNITARY COMBINATION OF

FSH AND hCG

Appl. No.:

Unassigned

Filing Date: Herewith

Examiner:

Herewith

Art Unit:

Herewith

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

Atty. Dkt. No. 052209-0143

## **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.

#### RELEVANCE OF EACH DOCUMENT

The listed documents were cited as being relevant during the prosecution of the corresponding International application. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

By Cristerian C

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone:

(202) 672-5404

Date December 2, 2005

Facsimile:

(202) 672-5399

Courtenay C. Brinckerhoff Attorney for Applicant

Registration No. 37,288

 $(\mathcal{C}_{i}, \mathcal{C}_{i}, \mathcal{C}_{i})$ 

10/559610

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collegion to unation unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known **Application Number** Unassigned INFORMATION DISCLOSURE STATEMENT BY APPLICANT **Filing Date** Herewith Marco Filicori **First Named Inventor** Date Submitted: December 2, 2005 1647 <del>Orrassigned</del> **Group Art Unit** RM DeBerry (use as many sheets as necessary) **Examiner Name** <del>Omassigned</del> Sheet Attorney Docket Number 052209-0143

·				U.S. PATENT DOCUMENTS	····	
Examiner Initials*	2	U.S. Patent Document		N	Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Fore Office <sup>3</sup>	eign Patent Do	ocument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>e</sub>
RMD	A1	EP	1 364 658	Α	APPLIED RESEARCH SYSTEMS	11/26/2003		
	A2	wo	00/67778	Α	APPLIED RESEARCH SYSTEMS	11/16/2000		
	A3	wo	03/022302	Α	APPLIED RESEARCH SYSTEMS	03/20/2003		
RMD	A4	wo	03/022303	Α	APPLIED RESEARCH SYSTEMS	03/20/2003		
								1

NON PATENT LITERATURE DOCUMENTS					
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>			
A5	FILICORI ET AL., "Stimulation and Growth of antral ovarian fillicles by selective LH activity administration in women," <i>Journal of Clinical Endrocrinology and Metabolism</i> , March 2002, pp. 1156-1161	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
A6	FILICORI ET AL., "Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome," <i>Journal of Clinical Endrocrinology and Metabolism</i> , vol. 84, no. 8, August 1999, pp. 2659-2663.				
A7	THOMPSON ET AL., "Gonadotrophin requirements of the developing follicle," Fertility and Sterility, vol. 63, no. 2, February 1995, pp. 273-276.				
	No. <sup>1</sup> A5	Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.  A5  FILICORI ET AL., "Stimulation and Growth of antral ovarian fillicles by selective LH activity administration in women," Journal of Clinical Endrocrinology and Metabolism, March 2002, pp. 1156-1161  A6  FILICORI ET AL., "Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome," Journal of Clinical Endrocrinology and Metabolism, vol. 84, no. 8, August 1999, pp. 2659-2663.  A7  THOMPSON ET AL., "Gonadotrophin requirements of the developing follicle," Fertility and Sterility, vol. 63, 100 pp. 100			

 Examiner Signature	ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH THROUGH (03/10/2008)

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.